OakChart

Lexicon Pharmaceuticals Inc

LXRXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

1.87+0.01 (0.54%)
2026-11-12 04:36 CET
Market cap
832.59 USD m
Revenue, TTM
38.54 USD m
Net income, TTM
-62.35 USD m
Free cash flow, TTM
-49.23 USD m
EPS diluted, TTM
-0.15
P/E
-
Compare

Price

LXRX against its 20, 50 and 200-day averages
2050200beatmiss
1.502.002.5019.7M39.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LXRXclose 1.8720-day 1.5750-day 1.79200-day 1.891.8752w high

30.2% under the 52-week high of 2.68 on 30 Jun 2026. 52-week low 1.10 on 30 Jan 2026. Last 15 sessions, 44.2% high to low

Volume 1.17× normal · the line is the 50-bar volume average

Profile

LXRX
52-week range, 49% of the way up
1.102.68

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

IndexRUT
Employees81
IPOApr 07, 2000
Beta1.04
ATR, 14d0.11
Rel volume1.17
Short float11.81%
Insider own50.79%
Inst own37.30%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap832.59M
Enterprise Value708.93M
Income-62.35M
Sales38.54M
Book/sh0.37
Cash/sh0.41
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees81
IPOApr 07, 2000

Ratios

P/E-
Forward P/E-
PEG-
P/S21.60
P/B5.08
P/C4.54
P/FCF-
EV/EBITDA-
EV/Sales18.39
Quick Ratio10.56
Current Ratio10.63
Debt/Eq0.36
LT Debt/Eq0.35
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.15
EPS next Y-0.21
EPS next Q-0.05
EPS this Y-13.62%
EPS next Y-32.75%
EPS next 5Y8.45%
EPS past 3/5Y39.13% 23.47%
Sales past 3/5Y610.25% 15.72%
EPS Y/Y TTM21.16%
Sales Y/Y TTM-45.62%
EPS Q/Q10.26%
Sales Q/Q-20.67%
EarningsNov 05 BMO
EPS/Sales Surpr.46.90% 171.43%

Ownership

Insider Own50.79%
Insider Trans0.01%
Inst Own37.30%
Inst Trans4.99%
ROA-27.84%
ROE-43.91%
ROIC-28.12%
Gross Margin97.79%
Oper. Margin-147.42%
Profit Margin-161.80%
SMA2019.09%
SMA504.56%
SMA200-1.05%
Trades-

Technical

Shs Outstand444.98M
Shs Float219.12M
Short Float11.81%
Short Ratio9.83
Short Interest25.88M
52W High2.68 -30.22%
52W Low1.10 70.00%
Volatility8.65% 6.52%
ATR (14)0.11
RSI (14)65.84
Beta1.04
Rel Volume1.17
Avg Volume2.63M
Volume3,086,512

Performance

Perf Week26.35%
Perf Month16.15%
Perf Quarter-20.09%
Perf Half Y-23.36%
Perf YTD62.61%
Perf Year19.87%
Perf 3Y85.15%
Perf 5Y-63.48%
Perf 10Y-88.62%
Recom1.67
Target Price4.51
Prev Close1.86
Price1.87
Change %0.54%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 28, 2026InitiatedCCantor FitzgeraldOverweight$8+327.8%
Mar 05, 2025DowngradeLLeerink PartnersOutperform → Market Perform$2 → $1-46.5%
Jun 17, 2024InitiatedHH.C. WainwrightBuy$10+434.8%
Apr 30, 2024InitiatedLLeerink PartnersOutperform$5+167.4%
Mar 07, 2023InitiatedJJefferiesHold$3+60.4%
Aug 12, 2022InitiatedPPiper SandlerOverweight$10+434.8%
Jan 29, 2021UpgradeJJP MorganUnderweight → Neutral$7+274.3%
Jan 29, 2021DowngradeWWedbushOutperform → Neutral$2 → $8+327.8%
Dec 08, 2020UpgradeCCitigroupNeutral → Buy
Nov 18, 2020UpgradeGGabelli & CoHold → Buy

Peers

Mkt cap
TickerCompanyMkt cap
ARDXArdelyx Inc786.79M
MLYSMineralys Therapeutics Inc1.43B
PHATPhathom Pharmaceuticals Inc510.51M
MNKDMannkind Corp1.35B
TVTXTravere Therapeutics Inc5.00B
KARDKardigan Inc1.47B
TECXTectonic Therapeutic Inc438.06M
VNDAVanda Pharmaceuticals Inc250.95M
RZLTRezolute Inc393.69M
DWTXDogwood Therapeutics Inc45.11M

Insider trading

latest 14 of 17
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Exton MichaelChief Executive OfficerNov 06 '26Buy1.6630,06449,999328,496Nov 09 08:13 AM
Swain Judith LDirectorJun 03 '26Option Exercise0.0089,3120174,486Jun 04 04:14 PM
Sullivan Diane E.DirectorJun 03 '26Option Exercise0.0089,3120126,122Jun 04 04:13 PM
SOBECKI CHRISTOPHER JDirectorJun 03 '26Option Exercise0.0089,3120293,177Jun 04 04:13 PM
Cheung IvanDirectorJun 03 '26Option Exercise0.0089,312089,312Jun 04 04:12 PM
BARKER SAM LDirectorJun 03 '26Option Exercise0.0089,3120213,771Jun 04 04:11 PM
Amouyal PhilippeDirectorJun 03 '26Option Exercise0.0089,3120374,486Jun 04 04:10 PM
DEBBANE RAYMONDDirectorJun 03 '26Option Exercise0.0089,31201,995,498Jun 04 04:09 PM
Artal Participations S.a r.l.DirectorApr 30 '26Option Exercise0.0020,421,7350175,156,062May 08 09:45 PM
DEBBANE RAYMONDDirectorFeb 25 '26Buy1.492,0002,9801,906,186Feb 27 08:33 AM
DEBBANE RAYMONDDirectorFeb 23 '26Buy1.47100,000147,0001,904,186Feb 25 07:00 AM
DEBBANE RAYMONDDirectorFeb 20 '26Buy1.48100,000147,7901,804,186Feb 23 07:49 AM
DEBBANE RAYMONDDirectorFeb 19 '26Buy1.4450,00071,9651,704,186Feb 23 07:49 AM
DEBBANE RAYMONDDirectorFeb 18 '26Buy1.32133,688176,4681,654,186Feb 18 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
XPHState Street SPDR S&P Pharmaceuticals ETFAUM: 516.35M
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWCiShares Micro-Cap ETFAUM: 1.22B
VHTVanguard Health Care ETFAUM: 21.51B
VFMOVanguard U.S. Momentum Factor ETFAUM: 1.82B

News

latest 14 of 100
  • Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
  • New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy (GlobeNewswire)
  • Lexicon's EPS Beat Owes Much To Dilution As SONATA-HCM And STENO1 Progress Collide With A Third ZYNQUISTA Delay (Earnings Whispers) +8.78%
  • Lexicon: Q3 Earnings Snapshot (Associated Press)
  • Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates (GlobeNewswire)
  • Lexicon Heads Into Q3 Needing Proof The Zynquista Refiling Finally Landed On Time (Earnings Whispers)
  • Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire)
  • Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy (GlobeNewswire)
  • Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin's Biological Effects in Cardiovascular Disease (GlobeNewswire)
  • Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM (Investing.com) +5.85%
  • Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences (GlobeNewswire)
  • Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure (GlobeNewswire)
  • LXRX Stock Edges Higher On $10M Payout From Novo Nordisk Retail Traders Highlight More Cash Milestones On The Horizon (Stocktwits)
  • Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.030-0.057-0.03011.254.146
2026Q22026-08-06-0.070-0.050-0.0730.693.995
2026Q12026-05-070.000-0.035-0.00321.109.795
2025Q42026-03-05-0.040-0.069-0.0435.493.145
2025Q32025-11-06-0.040-0.066-0.03514.184.655
2025Q22025-08-060.010-0.0750.00928.874.874
2025Q12025-05-13-0.070-0.095-0.0701.261.414
2024Q42025-03-06-0.090-0.127-0.09326.556.486
2024Q32024-11-12-0.180-0.163-0.1791.752.996
2024Q22024-08-01-0.170-0.177-0.1721.653.446
2024Q12024-05-02-0.200-0.180-0.1971.101.404
2023Q42024-03-11-0.200-0.217-0.1970.701.254
2023Q32023-11-08-0.210-0.215-0.2060.162.064
2023Q22023-08-03-0.220-0.175-0.2190.320.074
2023Q12023-05-02-0.170-0.179-0.1690.020.034
2022Q42023-03-02-0.160-0.134-0.1620.030.053

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY1.1600.9091.115322.07323.41
2020FY-0.530-0.740-0.52824.00156.75
2021FY-0.600-0.605-0.6030.300.19
2022FY-0.620-0.563-0.6150.140.14
2023FY-0.790-0.796-0.8011.201.75
2024FY-0.630-0.679-0.62631.0811.13
2025FY-0.140-0.167-0.14049.8047.46
2026FY--0.159--37.40
2027FY--0.211--17.87
2028FY--0.107--75.75
2029FY-0.036--155.85
2030FY-0.160--259.77

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-096244.380.0011.46
2026Q4S2026-11-066154.350.0011.26
2026Q4S2026-11-056145.980.0012.29
2026Q4S2026-10-2261011.220.7521.70
2026Q4S2026-10-2160111.210.7021.70
2026Q4S2026-10-2062111.210.7021.70
2026Q4S2026-10-1664111.210.7021.70
2026Q4S2026-09-2564011.220.7521.70
2026Q4S2026-08-0754013.3110.0021.70
2026Q4S2026-08-0652012.9610.0020.60
2026Q4S2026-07-2450010.021.5020.60
2026Q4S2026-07-2250010.011.5020.60
2026Q4S2026-07-2152010.011.5020.60
2026Q4S2026-05-0852310.011.5020.60

Estimate history

EPS, annual-1.169-1.1391.115-0.528-0.603-0.615-0.801-0.626-0.139-0.1494
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.179-0.093-0.070.009-0.035-0.043-0.003-0.073-0.032
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual91.68963.209322.07323.9950.2980.1391.20431.08149.80338.54
Period201720182019202020212022202320242025TTM
Sales, quarterly1.7526.5541.26228.86614.1825.49321.1020.69211.25
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual105.589105.926106.272141.496148.917188.726244.925361.492363.466444.978
Period201720182019202020212022202320242025MRQ
Shares, quarterly361.492361.492363.178363.399363.399363.466423.775444.937444.978
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue38.5449.8031.081.200.140.3024.00322.0763.21
Cost of Goods Sold Incl. D&A0.850.901.150.640.43-3.665.084.37
Gross Profit37.6948.9129.930.56-0.29-20.33316.9958.84
Selling, General and Administrative Excl. Other94.5097.82214.75172.31100.4787.10193.62146.91162.11
Research and Development57.2960.5082.8558.3352.3954.75149.3990.07100.24
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-56.81-48.91-184.82-171.75-100.76-87.09-173.28170.08-103.28
Interest Expense7.368.3415.5813.102.780.8014.5420.6820.78
Unusual Expense4.350.0012.300.000.000.006.1028.640.00
Net Income Before Taxes-62.35-50.34-200.40-177.12-101.94-87.76-58.57124.12-120.55
Income Taxes0.000.000.000.000.000.000.00-6.010.00
Consolidated Net Income-62.35-50.34-200.40-177.12-101.94-87.76-58.57130.13-120.55
Net Income From Continuing Operations-62.35-50.34-200.40-177.12-101.94-87.76-58.57130.13-120.55
Net Income-62.35-50.34-200.40-177.12-101.94-87.76-58.57130.13-120.55
EPS (Recurring)-0.13-0.14-0.60-0.80-0.62-0.60-0.491.29-1.14
EPS (Basic, Before Extraordinaries)-0.15-0.14-0.63-0.80-0.62-0.60-0.531.23-1.14
EPS (Diluted)-0.15-0.14-0.63-0.80-0.62-0.60-0.531.11-1.14
EBITDA-56.39-48.29-184.28-171.20-100.33-86.80-170.35173.74-99.60
Non-Operating Income (Expense)6.176.9112.297.731.600.13135.353.353.51
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense12.6312.5213.5014.3411.5210.589.6910.389.24
Price To Earnings Ratio-------3.97-
Price To Sales Ratio21.658.387.60281.002,277.341,925.7315.801.5011.12
Gross Margin97.7998.2096.3046.93-207.19-84.7398.4293.08
Operating Margin-147.42-98.21-594.63-14,264.95-72,489.21-29,224.83-722.1752.81-163.39
Net Margin-161.80-101.08-644.78-14,710.88-73,341.01-29,448.99-244.1140.40-190.71
Shares Outstanding444.98363.47361.49244.92188.73148.92141.50106.27105.93
Market Capitalization832.59832.59266.96374.74360.47586.65483.92441.03703.34

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue11.250.6921.105.4914.1828.871.2626.55
Cost of Goods Sold Incl. D&A0.170.140.220.320.160.210.210.47
Gross Profit11.080.5520.885.1714.0228.661.0626.08
Selling, General and Administrative Excl. Other25.5727.0921.8819.9526.2124.9226.7349.92
Research and Development16.1117.3412.6511.2018.6115.5715.1325.46
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-14.49-26.54-1.00-14.78-12.193.74-25.68-23.84
Interest Expense1.132.611.592.032.152.321.833.86
Unusual Expense0.004.350.000.000.00-0.008.90
Net Income Before Taxes-14.01-31.77-1.04-15.53-12.773.25-25.30-33.77
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-14.01-31.77-1.04-15.53-12.773.25-25.30-33.77
Net Income From Continuing Operations-14.01-31.77-1.04-15.53-12.773.25-25.30-33.77
Net Income-14.01-31.77-1.04-15.53-12.773.25-25.30-33.77
EPS (Recurring)-0.03-0.07-0.00-0.04-0.040.01-0.07-0.08
EPS (Basic, Before Extraordinaries)-0.03-0.07-0.00-0.04-0.040.01-0.07-0.09
EPS (Diluted)-0.03-0.07-0.00-0.04-0.040.01-0.07-0.09
EBITDA-14.40-26.44-0.89-14.66-12.043.91-25.50-23.71
Non-Operating Income (Expense)1.621.721.541.281.571.832.222.83
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.383.343.082.833.443.193.041.54
Price To Sales Ratio21.6525.338.978.396.925.885.358.59
Gross Margin98.4579.6298.9794.1998.8699.2883.6898.22
Operating Margin-128.84-3,835.26-4.72-269.07-85.9312.94-2,034.79-89.77
Net Margin-124.49-4,591.76-4.94-282.72-90.0411.27-2,004.36-127.16
Shares Outstanding444.98444.94423.77363.47363.40363.40363.18361.49
Market Capitalization832.591,066.07660.94417.91490.59343.46166.58266.96

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments96.23237.96170.03138.3686.74152.28271.66160.05310.79
Short Term Receivables2.383.471.010.030.010.4056.535.924.83
Inventories0.280.230.380.000.000.004.244.681.95
Other Current Assets3.004.535.132.482.165.055.322.674.43
Total Current Assets101.89246.19176.55140.8788.92157.72337.75173.32322.00
Net Property, Plant & Equipment9.187.327.518.893.441.5315.7015.8717.69
Total Investments and Advances29.000.000.000.000.000.000.000.000.00
Intangible Assets44.5444.5444.5444.5444.5444.5464.2694.6696.43
Deferred Tax Assets------4.144.514.88
Other Assets0.370.370.830.000.000.000.000.280.43
Total Assets184.99298.42229.43194.30136.91203.79421.86288.65441.42
Short Term Debt Incl. Current Port. of LT Debt6.241.181.291.291.0912.2011.611.1114.09
Accounts Payable3.0814.8014.3910.399.155.4712.1817.7638.76
Other Current Liabilities11.5529.2715.8711.4911.8829.1441.5517.8852.63
Total Current Liabilities20.8745.2531.5523.1722.1246.8165.3436.75105.49
Long Term Debt56.00104.90104.7754.001.190.61235.27243.89231.58
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities------4.1410.5310.90
Other Liabilities0.582.320.000.000.000.000.0023.8925.20
Total Liabilities77.45152.47136.3277.1723.3147.42304.76315.05373.16
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity107.54145.9593.11117.12113.59156.37117.10-26.4168.27
Total Shareholders Equity107.54145.9593.11117.12113.59156.37117.10-26.4168.27
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity107.54145.9593.11117.12113.59156.37117.10-26.4168.27
Total Liabilities & Stockholders Equity184.99298.42229.43194.30136.91203.79421.86288.65441.42
Book Value Per Share0.300.400.380.620.761.111.10-0.250.65
Tangible Book Value Per Share0.170.280.200.380.460.790.50-1.14-0.27
Full-Time Employees811032851358778184202174
Price to Book Ratio5.081.502.702.505.173.093.77-26.6413.31
Return on Assets-20.83-75.93-83.60-61.56-51.52-18.7236.63-33.02-17.76
Return on Equity-39.72-167.66-168.50-88.37-65.01-42.84286.97-938.23-109.00
Return on Invested Capital-30.78-79.89-89.51-59.57-76.45-37.3136.93-55.43-41.02
Quick Ratio4.875.445.586.084.023.375.104.593.03
Current Ratio4.885.445.606.084.023.375.174.723.05

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-62.35-50.34-200.40-177.12-101.94-87.76-58.57130.13-120.55
Depreciation0.420.620.530.550.430.292.933.653.68
Other Funds (Non Cash)15.708.765.5412.0112.2610.68-118.4144.3213.03
Funds from Operations-46.23-40.96-194.32-164.56-89.25-76.79-174.05172.09-103.83
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-3.00-26.8914.242.660.40-10.2331.08-58.29-44.77
Cash from Operating Activities-49.23-67.85-180.09-161.90-88.85-87.02-142.97113.81-148.61
Capital Expenditures0.000.00-1.03-0.47-1.33-1.22-0.09-0.07-0.10
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00171.400.00-
Purchase or Sale of Investments-70.71113.02-14.35-49.47-69.753.33209.44-155.78169.67
Purchase of Investments-208.41-139.84-328.75-223.34-133.95-34.26-58.55-322.38-119.99
Sale Or Maturity of Investments137.69252.86314.40173.8764.2037.59268.00166.60289.66
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-70.71113.02-15.38-49.94-71.082.11380.76-155.85169.58
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock97.750.07239.66138.0093.3434.4168.94-0.94-0.24
Repurchase of Common Pref Stock0.000.00-1.73-0.82-0.86-2.67-1.03-0.94-0.97
Sale of Common Pref Stock97.750.07241.39138.8294.2037.0869.970.000.73
Proceedsfrom Stock Options97.750.07241.39138.8294.2037.0869.970.000.73
Issuance or Reduction of Debt, Net-9.54-48.000.0049.9648.87-11.70-216.58-1.28-2.00
Change in Long Term Debt-9.54-48.000.0049.9648.87-11.70-216.58-1.28-2.00
Issuance of Long Term Debt52.730.000.0049.9648.870.000.000.0012.53
Reduction of Long Term Debt-62.26-48.000.000.000.00-11.70-216.58-1.28-14.53
Net Financing Active Other Cash Flow-2.84-0.570.000.000.000.000.000.000.00
Other Financing Activities Uses-2.84-0.570.000.000.000.000.000.000.00
Cash from Financing Activities85.37-48.50239.66187.96142.2122.71-147.64-2.23-2.24
Net Change in Cash-34.58-3.3344.19-23.88-17.72-62.2090.15-44.2718.73
Free Cash Flow-49.23-67.85-181.12-162.37-90.18-88.24-143.06113.74-148.70
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-------4.26-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00-6.010.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments183.20190.61170.6696.23115.95139.01
Short Term Receivables1.781.6411.782.382.332.18
Inventories1.211.200.280.280.160.17
Other Current Assets2.653.133.323.004.083.73
Total Current Assets188.84196.58186.03101.89122.53145.08
Net Property, Plant & Equipment8.278.578.889.189.496.59
Total Investments and Advances0.000.0029.0029.0029.0029.00
Intangible Assets44.5444.5444.5444.5444.5444.54
Other Assets0.370.370.370.370.370.37
Total Assets242.02250.06268.82184.99205.93225.58
Short Term Debt Incl. Current Port. of LT Debt1.641.641.646.241.640.91
Accounts Payable4.252.343.003.083.805.90
Other Current Liabilities11.8910.725.2611.5516.2828.03
Total Current Liabilities17.7714.719.9020.8721.7234.84
Long Term Debt57.9057.6056.0656.0063.3060.54
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities2.513.230.000.580.740.77
Total Liabilities78.1875.5365.9677.4585.7796.14
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity163.84174.53202.85107.54120.16129.44
Total Shareholders Equity163.84174.53202.86107.54120.16129.44
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity163.84174.53202.86107.54120.16129.44
Total Liabilities & Stockholders Equity242.02250.06268.82184.99205.93225.58
Book Value Per Share0.370.390.480.300.330.36
Tangible Book Value Per Share0.270.290.370.170.210.23
Full-Time Employees---81--
Price to Book Ratio5.085.015.273.483.792.79
Return on Assets-27.84-25.70-9.21-20.83-26.02-40.28
Return on Equity-43.91-40.21-16.01-39.72-45.92-65.30
Return on Invested Capital-6.32-13.69-0.40-9.50-6.961.71
Quick Ratio10.5613.2918.774.875.634.16
Current Ratio10.6313.3718.794.885.644.16

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-14.01-31.77-1.04-15.53-12.773.25
Depreciation0.100.100.110.120.150.18
Other Funds (Non Cash)2.387.972.622.733.102.36
Funds from Operations-11.53-23.701.68-12.69-9.525.79
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital3.4514.51-16.41-4.55-14.3111.20
Cash from Operating Activities-8.08-9.19-14.73-17.23-23.8316.99
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments11.18-16.46-70.264.8352.1215.48
Purchase of Investments-23.01-57.26-105.96-22.17-26.73-25.97
Sale Or Maturity of Investments34.2040.8035.7027.0078.8541.45
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities11.18-16.46-70.264.8352.1215.48
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00--0.000.000.00
Change in Capital Stock0.061.0296.600.070.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.061.0296.600.070.000.00
Proceedsfrom Stock Options0.061.0296.600.070.000.00
Issuance or Reduction of Debt, Net0.00-1.53-5.00-3.000.00-45.00
Change in Long Term Debt0.00-1.53-5.00-3.000.00-45.00
Issuance of Long Term Debt0.0052.730.000.000.000.00
Reduction of Long Term Debt0.00-54.26-5.00-3.000.00-45.00
Net Financing Active Other Cash Flow0.000.00-2.840.000.000.00
Other Financing Activities Uses0.000.00-2.840.000.000.00
Cash from Financing Activities0.06-0.5188.76-2.930.00-45.00
Net Change in Cash3.16-26.163.76-15.3328.29-12.52
Free Cash Flow-8.08-9.19-14.73-17.23-23.8316.99

Revenue breakdown

Pharmaceutical Preparations2024: 31.08M 2025: 49.80M
United States2024: 31.08M 2025: 49.80M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.81%25.9M219.1M2.71M
2026-10-1512.19%26.7M219.0M2.85M
2026-09-3011.79%25.8M219.0M2.96M
2026-09-1513.15%28.8M219.0M3.38M
2026-08-3113.49%29.5M218.6M3.34M
2026-08-1414.98%32.7M218.6M3.19M
2026-07-3115.29%32.8M214.7M3.42M
2026-07-1515.27%32.7M214.3M3.27M
2026-06-3014.36%30.8M214.3M3.14M
2026-06-1511.86%25.4M214.3M2.45M
2026-05-2912.90%26.2M203.2M2.64M
2026-05-1512.47%26.1M209.6M2.66M
2026-04-3010.33%23.9M231.0M2.42M
2026-04-1510.75%23.7M220.3M3.01M
2026-03-3112.76%22.9M179.8M2.91M
2026-03-1312.62%22.7M179.8M2.77M
2026-02-2712.87%23.1M179.8M2.45M
2026-02-1314.61%24.5M167.8M2.39M
2026-01-3013.97%24.6M175.9M2.38M
2026-01-1513.67%25.2M184.1M1.80M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.501.001.750.0019.3490.000.000.954-0.0220.000
call1.000.551.300.8210.09947.000.000.869-0.0250.001
call1.500.000.500.462.66363.000.000.748-0.0210.001
call2.000.050.100.051.30083610.000.437-0.0100.001
call2.500.000.050.042.35198.000.000.279-0.0130.001
call5.000.000.600.004.0970.000.000.111-0.0130.001
call7.500.000.750.005.1980.000.000.095-0.0140.000
put0.500.000.750.0013.7070.000.00-0.046-0.0220.000
put1.000.000.750.007.1370.000.00-0.131-0.0250.001
put1.500.000.250.203.99247.000.00-0.252-0.0210.001
put2.000.000.400.372.7894580.00-0.563-0.0100.001
put2.500.201.150.006.1500.000.00-0.808-0.0080.001
put5.002.603.803.5910.2391.000.00-0.889-0.0120.001
put7.505.006.300.0011.5800.000.00-0.905-0.0140.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-094Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-05SCHEDULE 13G/ASEC
2026-08-14EFFECTEffectiveness filing by commission orderSEC
2026-08-06S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-06S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-06SCHEDULE 13G/ASEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-05-084Statement of changes in beneficial ownership of securities2026-04-30SEC
2026-05-08SCHEDULE 13D/ASEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC
2026-05-068-KCurrent report2026-05-04SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-05-01SEC
2026-04-308-KCurrent report2026-04-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1150.00K100
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-022.72M800
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Artal Group S.A.39.43%
FMR LLC15.00%
Siren, L.L.C.9.97%
Sessa Capital IM, L.P.4.27%
BlackRock, Inc.3.91%
VANGUARD CAPITAL MANAGEMENT LLC2.23%
Point72 Asset Management, L.P.1.86%
GEODE CAPITAL MANAGEMENT, LLC1.32%
STATE STREET CORP1.11%
VANGUARD PORTFOLIO MANAGEMENT LLC0.53%

Funds

Fund% owned
Fidelity Growth Company Fund4.64%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.59%
iShares Russell 2000 ETF1.40%
Fidelity Growth Company K6 Fund1.36%
Select Biotechnology Portfolio1.28%
Fidelity Series Growth Company Fund1.14%
Fidelity Small Cap Index Fund0.61%
VANGUARD EXTENDED MARKET INDEX FUND0.58%
iShares Russell 2000 Growth ETF0.51%
VANGUARD RUSSELL 2000 INDEX FUND0.32%

OakChart. LXRX. Cached 15 minutes.